Enzalutamide, a second-generation therapeutic drug targeting the androgen receptor ligand-binding domain, has demonstrated effectiveness in inhibiting bladder cancer cells expressing the full-length androgen receptor (143, 144). Here, AR is linked to urinary bladder carcinoma.